Experimental results demonstrated that Eupafolin significantly inhibited the growth of breast cancer by the PI3K/AKT, MAPKs and NF-κB pathways, causing S-phase arrest, inhibiting angiogenesis and promoting apoptosis, which was partially mediated by Cav-1. Here, CAV1 is linked to breast cancer.